BRPI0517909A - cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-ho mopiperazino diidratado - Google Patents

cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-ho mopiperazino diidratado

Info

Publication number
BRPI0517909A
BRPI0517909A BRPI0517909-2A BRPI0517909A BRPI0517909A BR PI0517909 A BRPI0517909 A BR PI0517909A BR PI0517909 A BRPI0517909 A BR PI0517909A BR PI0517909 A BRPI0517909 A BR PI0517909A
Authority
BR
Brazil
Prior art keywords
sulfonyl
methyl
fluorisoquinolin
homopiperazine hydrochloride
dihydrate
Prior art date
Application number
BRPI0517909-2A
Other languages
English (en)
Inventor
Takeshi Ohshima
Hiroyoshi Hidaka
Masami Shiratsuchi
Kazuhiro Onogi
Toshiaki Oda
Original Assignee
Western Therapeutics Inst D
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517909(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Western Therapeutics Inst D, Kowa Co filed Critical Western Therapeutics Inst D
Publication of BRPI0517909A publication Critical patent/BRPI0517909A/pt
Publication of BRPI0517909B1 publication Critical patent/BRPI0517909B1/pt
Publication of BRPI0517909B8 publication Critical patent/BRPI0517909B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

CLORIDRATO DE (S) - (-) -1- (4-FLUORISOQUINOLIN-5-IL) SULFONIL-2-METIL-l,4-HOMOPIPERAZINO DIIDRATADO. Cloridrato de (S) -(-) -1- (4-fluorisoquinolin-5-I1) sulfonil-2-metil-l,4-homopiperazino diidratado; um processo para produzir o diidrato e uma composição medicinal contendo o diidrato. Este composto possui menor higroscopicidade do que os cristais anidros de cloridrato de (S)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado e é superior na estabilidade química, sendo por isso, útil como um medicamento.
BRPI0517909A 2004-11-29 2005-11-29 cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado BRPI0517909B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004344271 2004-11-29
PCT/JP2005/021844 WO2006057397A1 (ja) 2004-11-29 2005-11-29 （ｓ）－（－）－１－（４－フルオロイソキノリン－５－イル）スルホニル－２－メチル－１，４－ホモピペラジン塩酸塩・二水和物

Publications (3)

Publication Number Publication Date
BRPI0517909A true BRPI0517909A (pt) 2008-10-21
BRPI0517909B1 BRPI0517909B1 (pt) 2018-11-21
BRPI0517909B8 BRPI0517909B8 (pt) 2021-05-25

Family

ID=36498130

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517909A BRPI0517909B8 (pt) 2004-11-29 2005-11-29 cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado

Country Status (24)

Country Link
US (1) US7858615B2 (pt)
EP (1) EP1818329B1 (pt)
JP (1) JP4016060B2 (pt)
KR (1) KR101253369B1 (pt)
CN (1) CN101068806B (pt)
AT (1) ATE465159T1 (pt)
AU (1) AU2005308060B2 (pt)
BR (1) BRPI0517909B8 (pt)
CA (1) CA2589237C (pt)
CY (1) CY1112406T1 (pt)
DE (1) DE602005020835D1 (pt)
DK (1) DK1818329T3 (pt)
EA (1) EA011283B1 (pt)
ES (1) ES2345562T3 (pt)
HK (1) HK1112898A1 (pt)
MX (1) MX2007006322A (pt)
MY (1) MY139797A (pt)
NO (1) NO339021B1 (pt)
NZ (1) NZ555560A (pt)
PL (1) PL1818329T3 (pt)
PT (1) PT1818329E (pt)
TW (1) TWI354670B (pt)
WO (1) WO2006057397A1 (pt)
ZA (1) ZA200704201B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290827A (ja) * 2005-04-13 2006-10-26 Kowa Co 緑内障予防又は治療剤
AU2006285915B2 (en) 2005-08-30 2011-02-24 Asahi Kasei Pharma Corporation Sulfonamide compound
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
CN101622243B (zh) 2007-02-28 2013-12-04 旭化成制药株式会社 磺酰胺衍生物
JP5234825B2 (ja) 2007-07-02 2013-07-10 旭化成ファーマ株式会社 スルホンアミド化合物及びその結晶
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2012026529A1 (ja) 2010-08-26 2012-03-01 興和株式会社 イソキノリン誘導体又はその塩の新規製造方法
EP3626245B1 (en) * 2013-04-24 2021-05-05 Kyushu University, National University Corporation Therapeutic agent for eyeground disease
PL3199161T3 (pl) * 2014-09-25 2022-04-11 Kowa Company, Ltd. Preparat farmaceutyczny
WO2016111688A1 (en) * 2015-01-08 2016-07-14 Hewlett-Packard Development Company, L.P. Mobile printers
CN107216311B (zh) * 2016-03-21 2019-09-03 山东诚创医药技术开发有限公司 (s)-4-[(4-氟代异喹啉-5-基)磺酰基]-3-甲基-1,4-二氮杂环庚烷盐酸盐的精制方法
CN106496189A (zh) * 2016-10-10 2017-03-15 江苏礼华生物技术有限公司 盐酸Ripasudil晶型
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
ES2972617T3 (es) 2018-12-17 2024-06-13 D Western Therapeutics Inst Inc Nueva forma de sulfonamida de isoquinolina
CN113906017B (zh) * 2019-06-21 2024-07-02 广州润尔眼科生物科技有限公司 作为rock蛋白激酶抑制剂的异喹啉酮的衍生物及其应用
CN114644618A (zh) * 2020-12-21 2022-06-21 广州润尔眼科生物科技有限公司 一种作为rock蛋白激酶抑制剂的异喹啉酮型化合物的盐型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734531B2 (ja) * 1995-06-29 2006-01-11 旭化成ファーマ株式会社 １−（５−イソキノリンスルホニル）ホモピペラジン塩酸塩３水和物
DE69606721T2 (de) * 1995-07-03 2000-06-21 Asahi Kasei Kogyo K.K., Osaka 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid
JP3834663B2 (ja) * 1996-02-02 2006-10-18 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリン誘導体及び医薬
WO1999020620A1 (fr) * 1997-10-22 1999-04-29 Nippon Shinyaku Co Ltd Derive d'isoquinoleine et medicament

Also Published As

Publication number Publication date
CA2589237A1 (en) 2006-06-01
ES2345562T3 (es) 2010-09-27
EP1818329A1 (en) 2007-08-15
AU2005308060B2 (en) 2011-02-17
ZA200704201B (en) 2008-09-25
NO339021B1 (no) 2016-11-07
MX2007006322A (es) 2007-06-19
NZ555560A (en) 2008-10-31
KR101253369B1 (ko) 2013-04-11
JP4016060B2 (ja) 2007-12-05
US7858615B2 (en) 2010-12-28
NO20072382L (no) 2007-08-23
CA2589237C (en) 2013-05-14
BRPI0517909B1 (pt) 2018-11-21
MY139797A (en) 2009-10-30
KR20070084127A (ko) 2007-08-24
JPWO2006057397A1 (ja) 2008-06-05
BRPI0517909B8 (pt) 2021-05-25
DK1818329T3 (da) 2010-07-19
CN101068806A (zh) 2007-11-07
HK1112898A1 (pt) 2008-09-19
PL1818329T3 (pl) 2010-10-29
EP1818329B1 (en) 2010-04-21
AU2005308060A1 (en) 2006-06-01
PT1818329E (pt) 2010-06-22
ATE465159T1 (de) 2010-05-15
CN101068806B (zh) 2012-02-01
TWI354670B (en) 2011-12-21
EA011283B1 (ru) 2009-02-27
DE602005020835D1 (de) 2010-06-02
CY1112406T1 (el) 2015-12-09
WO2006057397A1 (ja) 2006-06-01
EA200701156A1 (ru) 2007-10-26
US20080021018A1 (en) 2008-01-24
EP1818329A4 (en) 2009-08-05
TW200630359A (en) 2006-09-01

Similar Documents

Publication Publication Date Title
BRPI0517909A (pt) cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-ho mopiperazino diidratado
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE553077T1 (de) Peptidaseinhibitoren
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
CR9421A (es) Compuestos heterociclicos fusionados
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NO20055591L (no) Antivirale fosfonatanaloger
SE0202838D0 (sv) Chemical compounds
NO20064032L (no) DPP-IV inhibitorer
EA200702670A1 (ru) Препарат тиенопиридинового ингибитора агрегации тромбоцитов
EA200870460A1 (ru) Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
DK1756052T3 (da) Forbedret fremgangsmåde til at fremstille 3-hydroxy-4-hydroxymethyl-pyrrolidin-forbindelser
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
DK1723140T3 (da) Fremgangsmåde til fremstilling af tryptase-inhibitorer
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
DK1529043T3 (da) Fremgangsmåde til fremstilling af 2-methylpiperazin-derivater
ATE481408T1 (de) Reinigung von beta-lactam-verbindungen
DK1601361T3 (da) Pyridylsulfonamidopyrimidiner til behandling af iabetisk nefropati
SE0403003D0 (sv) Chemical compound 1
GB0314299D0 (en) Chemical compounds
DK1392652T3 (da) Fremgangsmåde til fremstilling af 1,3-disubstituerede 2-nitroguanidiner

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2750 DE 19-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.